Active ingredientZonisamideCat. No. P-Z026-001CAS 68291-97-4Family · Pharmaceutical analytical standards
Zonisamide
A sulphonamide-structured antiepileptic, discovered in 1972 and first marketed in Japan in 1989, then in the United States in 2000 and in Europe in 2005: it is used for focal seizures. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?Chemically it resembles no other antiepileptic; and in 2009 in Japan it also began to be used in Parkinson's disease, together with levodopa, to improve motor symptoms.
Go to the active ingredient →Active ingredientZonisamideCat. No. P-Z026-001CAS 68291-97-4
Pharmacopoeial impurityZonisamide USP Related Compound ACat. No. P-Z026-002CAS 342623-49-8
Pharmacopoeial impurityZonisamide USP Related Compound A Sodium SaltCat. No. P-Z026-003CAS 73101-64-1
Pharmacopoeial impurityN,N-Dimethyl ZonisamideCat. No. P-Z026-004CAS 1217201-89-2
Pharmacopoeial impurityZonisamide USP Related Compound CCat. No. P-Z026-005
MetaboliteZonisamide MetaboliteCat. No. P-Z026-006CAS 74538-97-9
MetaboliteZonisamide Metabolite GlucuronideCat. No. P-Z026-007CAS 84557-58-4
MetaboliteZonisamide N-GlucuronideCat. No. P-Z026-008
Isotopically labelledZonisamide-13C2-15NCat. No. P-Z026-009CAS 1188265-58-8
Impurity1,2-Benzisoxazol-3-ylacetic AcidCat. No. P-Z026-010CAS 4865-84-3
ImpurityN-Acetyl ZonisamideCat. No. P-Z026-011CAS 68936-43-6
ImpurityN-Methyl ZonisamideCat. No. P-Z026-012CAS 68292-02-4No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.